News

FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S.
Managed Healthcare Executive3d
FDA Grants Orphan Drug Exclusivity to Mesoblast's Ryoncil for Pediatric GVHD
The FDA has granted Mesoblast’s stem cell therapy, Ryoncil (remestemcel-L), seven years of orphan drug exclusivity for the ...
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Eton Pharmaceuticals is able to buy orphan drugs from large pharma companies, where they are too small to matter. Read why ...
Morningstar8d
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory ...
Targeted Oncology11d
THE001, Novel Sarcoma Treatment, Earns FDA Orphan Drug Designation
THE001, a thermosensitive doxorubicin liposome for soft tissue sarcomas, received FDA orphan drug designation, offering ...
Mesoblast Limited: FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years ...
US FDA Orphan Drug Rare Disease Market Clinical Trials Drug Sales Insight 2030
Kuick Research Report Gives Detailed Insight On More Than 1400 FDA Orphan Designated Drugs And Highlights More Than USD 190 Billion Opportunity</p ...
Nasdaq8d
Mesoblast Secures FDA Orphan-Drug Approval For Ryoncil
(RTTNews) - Mesoblast (MESO, MSB.AX) announced that it has received seven years of orphan-drug exclusive approval from U.S ... exclusivity means that the FDA will not approve another mesenchymal ...